Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.

Background: Adoptive cell transfer (ACT) is a promising cancer immunotherapeutic strategy that remains ineffective for a large subset of patients. ACT with memory CD8+ T cells (T) has been shown to have superior efficacy compared to traditional ACT with effector CD8+ T cells (T). T and T have complementary physiological advantages for immunotherapy, but previous publications have not examined ACT using a combination of T and T.

Methods: Splenocytes harvested from Ly5.1+/C57BL/6 mice during and after infection with lymphocytic choriomeningitis virus (LCMV) were used to generate bona fide effector and memory CD8+ T cells specific for the LCMV epitope peptide GP33. Congenic Ly5.2+/C57BL/6 mice were inoculated with B16F10 melanoma cells transfected to express very low levels of GP33, then treated with ACT 7 days later with GP33-specific T, T, or a combination of T + T.

Results: Inhibition of melanoma growth was strongest in mice receiving combinatorial ACT. Although combinatorial ACT and memory ACT resulted in maximal intratumoral infiltration of CD8+ T cells, combinatorial ACT induced stronger infiltration of endogenous CD8+ T cells than T ACT and a stronger systemic T cell responsiveness to tumor antigen. In vitro assays revealed rapid but transient melanoma inhibition with T and gradual but prolonged melanoma inhibition with T; the addition of T enhanced the ability of T to inhibit melanoma in a manner that could be reproduced using conditioned media from activated T and blocked by the addition of anti-IL-2 blocking antibody.

Conclusions: These findings suggest that a novel combinatorial approach that takes advantage of the unique and complementary strengths of tumor-specific T and T may be a way to optimize the efficacy of adoptive immunotherapy.